SLC5A2 and metabolic dysfunction-associated steatotic liver disease: In this study, we systematically evaluated the role and potential mechanisms of the SGLT2 inhibitor empagliflozin in NAFLD by integrating Mendelian randomization (MR) analysis with in vivo experiments.